Establishing a Core Outcome Set for Autosomal Dominant Polycystic Kidney Disease: Report of the Standardized Outcomes in Nephrology-Polycystic Kidney Disease (SONG-PKD) Consensus Workshop

The omission of outcomes that are of relevance to patients, clinicians, and regulators across trials in autosomal dominant polycystic kidney disease (ADPKD) limits shared decision making. The Standardized Outcomes in Nephrology-Polycystic Kidney Disease (SONG-PKD) Initiative convened an international consensus workshop on October 25, 2018, to discuss the identification and implementation of a potential core outcome set for all ADPKD trials. This article summarizes the discussion from the workshops and the SONG-PKD core outcome set. Key stakeholders including 11 patients/caregivers and 47 health professionals (nephrologists, policy makers, industry, and researchers) attended the workshop. Four themes emerged: "Relevance of trajectory and impact of kidney function" included concerns about a patient's prognosis and uncertainty of when they may need to commence kidney replacement therapy and the lack of an early prognostic marker to inform long-term decisions; "Discerning and defining pain specific to ADPKD" highlighted the challenges in determining the origin of pain, adapting to the chronicity and repeated episodes of pain, the need to place emphasis on pain management, and to have a validated measure for pain; "Highlighting ADPKD consequences" encompassed cyst-related complications and reflected patient's knowledge because of family history and the hereditary nature of ADPKD; and "Risk for life-threatening but rare consequences" such as cerebral aneurysm meant considering both frequency and severity of the outcome. Kidney function, mortality, cardiovascular disease, and pain were established as the core outcomes for ADPKD.

Contributors

Yeoungjee Cho, Allison Tong, Jonathan C Craig, Reem A Mustafa, Arlene Chapman, Ronald D Perrone, Curie Ahn, Kevin Fowler, Vicente Torres, Ron T Gansevoort, Albert C M Ong, Helen Coolican, Juliana Tze-Wah Kao, Tess Harris, Talia Gutman, Jenny I Shen, Andrea K Viecelli, David W Johnson, Eric Au, Ragada El-Damanawi, Charlotte Logeman, Angela Ju, Karine E Manera, Michel Chonchol, Dwight Odland, David Baron, York Pei, Benedicte Sautenet, Anjay Rastogi, Ankit Sharma, Gopala Rangan, SONG-PKD Workshop Investigators

Publication

Journal: American Journal of Kidney Diseases
Volume: 77
Issue: 2
Pages: 255 - 263
Year: 2021
DOI: 10.1053/j.ajkd.2020.05.024

Further Study Information

Current Stage: Completed
Date:
Funding source(s): PKD Foundation Australia


Health Area

Disease Category: Kidney disease

Disease Name: Polycystic kidney disease

Target Population

Age Range: 18 - 100

Sex: Either

Nature of Intervention: Any

Stakeholders Involved

- Clinical experts
- Consumers (caregivers)
- Consumers (patients)
- Epidemiologists
- Patient/ support group representatives
- Pharmaceutical industry representatives
- Policy makers
- Regulatory agency representatives
- Researchers

Study Type

- COS for clinical trials or clinical research

Method(s)

- Consensus conference